COLLEGIUM PHARMACEUTICAL, INC
For the period ended May 12, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 12, 2026 · Filed May 12, 2026
Use the contents to explore the available documents and sections.
COLL$24.21-3.8%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Financial Guidance for 2026
Financial Guidance for 2026
Collegium raises its full-year 2026 financial guidance for Product Revenues, Net, and Adjusted EBITDA, which now includes the anticipated impact of the acquisition of AZSTARYS.
| Prior | Updated | |
| Product Revenues, Net | $805 to $825 million | $865 to $895 million |
|---|---|---|
| JORNAY PM Revenue, Net | $190 to $200 million | Unchanged |
| AZSTARYS Revenue, Net | N/A | $60 to $70 million |
| Adjusted EBITDA | $455 to $475 million | $475 to $500 million |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.